Add this topic to your myFT Digest for news straight to your inbox
Chief executive says customers very willing to pay for Wegovy from their own pockets
Start-ups say new technology could help end animal testing by pharma companies
Investing in new oncology drugs without building up an effective arsenal against infections is a false economy
Danish drugmaker reports better than expected earnings for 2023
Mounjaro has achieved 22.5 per cent loss of body weight in trials
Chair of 100 Days Mission warns of huge economic cost if world cannot act swiftly to tackle pathogens
Danish biotech group Zealand Pharma is developing an alternative obesity treatment to compete with big rivals
Swedish trial finds ‘high accuracy’ in identifying protein associated with toxic build-up in the brain
Chief of Google’s AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships
Huge demand for weight-loss treatments offers rich rewards but the leading pharma groups will not cede ground easily
Argenx is one of the bloc’s largest biotech companies but its shareholder base is dominated by US specialist investors
Danish manufacturer of Wegovy invests in two start-ups as part of efforts to stay ahead in major new market
Lender invests in venture fund 4Bio Capital as it says UK sector has ‘significant untapped potential’
Potential remedy targets leading antibiotic-resistant pathogen that causes life-threatening infections in patients
Novo Nordisk Foundation is little known outside Nordic countries but is bigger than Wellcome or Gates
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
US biotech company’s stock worth nearly $500 at its peak in August 2021, currently trades at less than $87
Belfast-based CV6 Therapeutics announced MHRA approval for trials of novel therapy pill
Paul Hudson needs to convince investors that pharma group’s new blockbuster drugs will be successful
Paul Hudson is meeting investors to explain multibillion-euro push to get drug candidates to market
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
Pharma group behind blockbuster drug wants to supersize its market impact
Science secretary Michelle Donelan signs post-Brexit deal to rejoin €96bn research scheme
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
International Edition